NextCure Inc. (NXTC)

AI Score

Unlock

0.40

-0.04 (-8.47%)

At close: Apr 02, 2025, 3:59 PM

0.39

-3.75%

After-hours: Apr 02, 2025, 07:53 PM EDT

-8.47% (1D)

Bid	0.29
Market Cap	11.29M
Revenue (ttm)	n/a
Net Income (ttm)	n/a
EPS (ttm)	-1.99
PE Ratio (ttm)	-0.2
Forward PE	-0.53
Analyst	Buy

Ask	0.45
Volume	288,671
Avg. Volume (20D)	89,838
Open	0.42
Previous Close	0.44
Day's Range	0.35 - 0.47
52-Week Range	0.35 - 2.49
Beta	0.71

About NXTC

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune sup...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date May 9, 2019

Employees 43

Stock Exchange NASDAQ

Ticker Symbol NXTC

Website https://www.nextcure.com

Full Company Profile

Analyst Forecast

According to 2 analyst ratings, the average rating for NXTC stock is "Buy." The 12-month stock price forecast is $3.5, which is an increase of 768.27% from the latest price.

Stock Forecasts

Why Price Moved

4 months ago

+1.55%

NextCure shares are trading higher after the compa... Unlock content with Pro Subscription

6 months ago

-5%

NextCure shares are trading lower. The company announced results from its Phase 1b study of NC410.

News

1 year ago · investorplace.com

Wall Street's Favorite Penny Stocks? 7 Names That Could Make You Filthy Rich

The bullish sentiment in the market is leading some investors to look at risk-on assets. Bitcoin may be an option, but for investors who prefer to stay in stocks, it may be time to look for some of th...

1 year ago · zacks.com

Here's Why NextCure, Inc. (NXTC) Looks Ripe for Bottom Fishing

NextCure, Inc. (NXTC) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mea...